Sandbox Reserved 911: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 28: | Line 28: | ||
[[Image:AEA image.png|200 px|left|thumb|[http://en.wikipedia.org/wiki/File:Anandamide_skeletal.svg Anandamide]]] | [[Image:AEA image.png|200 px|left|thumb|[http://en.wikipedia.org/wiki/File:Anandamide_skeletal.svg Anandamide]]] | ||
FAAH plays a role in endocannabinoid signaling that has intriguing potential as a drug target. This signaling system consits of endocannabinoid ligands (such as AEA), two G protein-coupled receptors (CB1 and CB2), and the enzymes that synthesize and degrade (such as FAAH) the signaling lipids. Previous research exploring the potential of regulating endocannabinoid signaling through the CB1 and CB2 receptors. However, molecules found to activate these receptors, while providing the intended pain relief, also produce many undesirable side effects, such as decreased cognition and motor control. On the other hand, research involving FAAH inhibitors has shown that blocking this part of the pathway reduces pain without the unwanted side effects seen through CB1/CB2 activation. **add more?** (2VYA) | |||
1MT5 <ref>PMID:12459591</ref> | 1MT5 <ref>PMID:12459591</ref> | ||
